900164-96-7

Upstream product

• 696-59-3 cis,trans-2,5-dimethoxytetrahydrofuran 
• 114715-39-8 (R)-1-benzyl-3-aminopyrrolidine 
• 110-52-1 1,4-dibromo-butane 

Downstream Products

• 913702-34-8 (R)-1,3'-bipyrrolidine dihydrochloride 
• 900164-95-6 (R)-[1,3']bipyrrolidinyl 

Relevant academic research and scientific papers

Chiral 3-aminopyrrolidines as a rigid diamino scaffold for organocatalysis and organometallic chemistry

Over 20 new and easily prepared diamines were screened for the asymmetric Morita-Baylis-Hillman reaction. Chiral non-racemic 3-(N,N-dimethylamino)-1- methylpyrrolidine was found to promote efficiently the reaction of methyl vinyl ketone and substituted benzaldehydes. Enantiomeric excesses up to 73% were reached with electron-deficient benzaldehyde derivatives. After a simple deprotonation, one of these diamines was transformed into a chiral mixed aggregate for the enantioselective synthesis of (R)-1-o-tolylethanol with 76% ee.

PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS

A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof.and their preparation and use as A2A receptor agonists

ORGANIC COMPOUNDS

A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals (I) wherein R1 R2 R3, R4 and W are as defined herein.

PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS

Compounds of formula (I) in free or salt form, wherein R1, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A2A receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY

Compounds of (I), or stereoisomers or pharmaceutically acceptable salts thereof, where W, R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A2A receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.